TL;DR
This study identifies α-Actinin1 (ACTN1) as a key driver of gastric cancer (GC) progression, promoting tumor growth, invasion, and metastasis. ACTN1 achieves this by activating the AKT/GSK3β/β-catenin signaling pathway, which in turn facilitates the epithelial-mesenchymal transition (EMT). These findings position ACTN1 as a potential therapeutic target for GC.
What Problem Does This Paper Address?
Gastric cancer (GC) remains a significant global health challenge, characterized by late diagnosis, high rates of metastasis, and poor survival rates. While various molecular mechanisms contribute to GC development, the specific roles of certain proteins, like α-Actinin1 (ACTN1), in this context have remained largely unexplored. ACTN1 is an actin-binding protein known to be involved in cell adhesion and migration, and its dysregulation has been implicated in other cancers. However, its precise function and underlying mechanisms in GC were unclear, necessitating research to identify novel therapeutic targets and understand GC pathogenesis.
Methods
The researchers employed a multi-pronged approach to investigate ACTN1's role in GC:
- Bioinformatics Analysis: They utilized public databases like the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) to analyze ACTN1 expression levels in GC tissues compared to normal tissues. Kaplan-Meier analysis was used to assess the correlation between ACTN1 expression and patient survival.
- Experimental Validation:
- Western Blotting (WB) and RT-qPCR: These techniques were used to confirm ACTN1's differential expression at both protein and mRNA levels in GC tissues and cell lines.
- Cell Culture and Transfection: Human GC cell lines were cultured, and their ACTN1 levels were manipulated using overexpression plasmids and small interfering RNAs (siRNAs) to study the functional consequences.
- Functional Assays: * Cell Proliferation Assay (EdU incorporation): To assess the impact of ACTN1 on cell growth.
- Apoptosis Assay (Flow Cytometry): To determine if ACTN1 affects programmed cell death.
- Wound-Healing Assay and Transwell Assay: To evaluate cell migration and invasion capabilities, key aspects of metastasis.
- Immunofluorescence: To visualize the localization of key proteins (e.g., E-cadherin, Vimentin, β-catenin) within cells.
- Immunohistochemistry: To examine ACTN1 protein expression in tissue samples.
- Mechanistic Studies: Western blotting was used to investigate the expression and phosphorylation status of key signaling molecules in the AKT/GSK3β/β-catenin pathway. The effect of an AKT inhibitor (MK2206) was also assessed to confirm the pathway's involvement.
Datasets
The study utilized publicly available datasets for initial analysis and validation:
- Gene Expression Omnibus (GEO) Datasets: GSE26942, GSE54129, GSE56807, GSE118916, GSE79973, GSE84437, and GSE62254 were used to analyze ACTN1 expression and its correlation with clinical and survival information in GC.
- The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) Databases: These were accessed via the GEPIA web server for further analysis of ACTN1 expression in GC.
No new datasets or benchmarks were introduced in this paper.
Key Insights and Ideas
- ACTN1 as a GC Oncogene: The most significant insight is the identification of ACTN1 as a novel oncogene in gastric cancer, directly promoting its development and progression. This moves beyond its previously known roles in other cellular processes.
- The AKT/GSK3β/β-Catenin Axis: The study elucidates a critical molecular pathway through which ACTN1 exerts its effects. ACTN1's activation of AKT leads to the inhibition of GSK3β, which in turn stabilizes β-catenin, promoting its nuclear translocation and the transcription of downstream genes involved in tumorigenesis and EMT.
- EMT Regulation by ACTN1: ACTN1 is shown to be a key regulator of the epithelial-mesenchymal transition (EMT) in GC. It promotes the expression of mesenchymal markers (Vimentin, Snail) and downregulates epithelial markers (E-cadherin), facilitating cell detachment and invasion.
- Therapeutic Potential: The findings strongly suggest that ACTN1 could be a valuable therapeutic target for GC, offering a new avenue for treatment strategies.
Key Results
- ACTN1 Upregulation in GC: High-throughput sequencing and public database analysis revealed significantly elevated ACTN1 expression in GC tissues compared to adjacent normal tissues. This upregulation was consistently observed across multiple datasets.
- Poor Prognosis Correlation: ACTN1 overexpression was strongly associated with a poor overall survival rate in GC patients, highlighting its clinical significance.
- ACTN1 Promotes GC Cell Growth and Metastasis: Functional studies demonstrated that ACTN1 overexpression enhanced GC cell proliferation, invasion, and migration, while its knockdown had the opposite effect. Conversely, ACTN1 overexpression inhibited apoptosis.
- Mechanism Confirmation: Treatment with an AKT inhibitor (MK2206) significantly reversed the migration-promoting effects of ACTN1 overexpression, confirming the critical role of the AKT/GSK3β/β-catenin pathway.
Limitations and Future Work
The authors acknowledge several limitations:
- Lack of In Vivo Experiments: The study primarily relied on in vitro cell-based assays. Future research should include in vivo models (e.g., xenograft models) to validate these findings in a more complex biological system.
- Limited Sample Size: While multiple datasets were used, the authors note that the sample size for some analyses could be expanded.
- Unexplored Upstream Mechanisms: The study did not fully elucidate how ACTN1 itself becomes upregulated or how it initiates the phosphorylation of AKT. Further investigation into these upstream regulatory mechanisms is warranted.
- Potential for Other Pathways: While the AKT/GSK3β/β-catenin pathway is identified as a key mechanism, the authors suggest that other signaling pathways might also contribute to ACTN1's functions in GC.
Future work should focus on translating these findings into clinical applications, exploring ACTN1-targeted therapies, and further dissecting the intricate molecular network regulated by ACTN1 in gastric cancer.
Summary updated